|Bid||84.49 x 800|
|Ask||84.51 x 1800|
|Day's range||84.33 - 86.50|
|52-week range||59.80 - 86.50|
|Beta (3Y monthly)||0.29|
|PE ratio (TTM)||26.65|
|Earnings date||30 Jul 2019|
|Forward dividend & yield||2.20 (2.58%)|
|1y target est||88.93|
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.
At a meeting with the investment community today, Merck (MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term. “Merck is very well positioned to pursue its mission to save and improve lives,” said Kenneth C. Frazier, Merck chairman and chief executive officer.
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
LYNPARZA is the Only PARP Inhibitor Approved in Japan
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
Marks First Approval for KEYTRUDA in SCLC
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Tri
British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April. Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said.
Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.
On April 2, Merck & Co. issued a press release announcing the successful completion of its cash tender offer for Immune Design, with 86.75% of the target’s total outstanding common stock tendered on a fully diluted basis.
On its first-quarter earnings conference call, Merck & Co. (MRK) guided for 2019 revenue of $43.9 billion–$45.1 billion, a YoY (year-over-year) rise of 4%–7% driven by its Oncology, Hospital and Specialty, Vaccines, and Animal Health segments.
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Analysts say that the event will be vital for the pharmaceutical company as it seeks to show investors it can build on a strong run in recent years.